Idelalisib Terminated Phase 2 Trials for Follicular Lymphoma (FL) / Small Lymphocytic Lymphoma (SLL) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02258529Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma